03.23.15
Takeda Pharmaceutical Co. has licensed exclusive rights to use ImmunoGen’s ADC technology to develop and commercialize targeted anticancer therapeutics for as many as two undisclosed targets. Takeda has the option to take a license for a third target for an additional upfront fee.
ImmunoGen will receive $20 million upfront, and for each target, is eligible to receive milestone payments of as much as $210 million plus royalties on sales of any resulting ADC products. Takeda is responsible for the development, manufacturing and marketing of any resulting ADC products.
“Takeda shares our commitment to developing novel anticancer therapies that meaningfully improve the lives of patients, and we look forward to collaborating with them to create important new ADC product candidates,” said Daniel Junius, ImmunoGen president and chief executive officer.
“ADC technology is a critically important tool in addressing unmet needs in oncology,” said Christopher Claiborne, Ph.D., Head of the Oncology Drug Discovery Unit at Takeda. “By partnering with ImmunoGen, we are able to leverage this important technology in Takeda’s R&D program and bring novel agents through the clinic.”
ImmunoGen will receive $20 million upfront, and for each target, is eligible to receive milestone payments of as much as $210 million plus royalties on sales of any resulting ADC products. Takeda is responsible for the development, manufacturing and marketing of any resulting ADC products.
“Takeda shares our commitment to developing novel anticancer therapies that meaningfully improve the lives of patients, and we look forward to collaborating with them to create important new ADC product candidates,” said Daniel Junius, ImmunoGen president and chief executive officer.
“ADC technology is a critically important tool in addressing unmet needs in oncology,” said Christopher Claiborne, Ph.D., Head of the Oncology Drug Discovery Unit at Takeda. “By partnering with ImmunoGen, we are able to leverage this important technology in Takeda’s R&D program and bring novel agents through the clinic.”